Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
ConclusionSubstantial heterogeneity in the use of NST with HR+/HER2-breast cancer exists in Europe. While stringent guidelines are available for its use in triple-negative and HER2+ breast cancer, there is a need for the development of and adherence to well-defined recommendations for HR+/HER2-breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Austria Health | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Hungary Health | Neoadjuvant Therapy | Study | Switzerland Health